Knight ADRC in the News

…Alzheimer’s researchers and clinicians aren’t convinced the Quest test is backed by sound scientific research. The possibility of false-positive results is high, as is the likelihood that older adults won’t understand the significance of their results, they say. The test should be taken only under a physician’s supervision, if at all, they advise. And, priced originally at $399 (recently discounted to $299) and not covered by insurance, it isn’t cheap.

In search of ways to prevent these destructive tau tangles, researchers at Washington University School of Medicine in St. Louis have identified a key step in their development. Intervening at this step potentially could forestall the destructive cascade of events that results in brain damage, the researchers said. The findings are published Sept. 20 in the journal Molecular Psychiatry.

The Food and Drug Administration (FDA) recently gave full approval to Leqembi (lecanemab) for patients in the early stages of Alzheimer’s disease. Barbara Joy Snider, MD, PhD, answers questions about the drug.

The Knight ADRC’s own Myrtis Spencer, Dotti McDowell, Maribel Chebuske, and Heather Klemp were excited to attend the Affinia Health Back-to-School Bash at their N. Florissant Health Center to raise awareness on Alzheimer Disease.

NIH-supported study lays groundwork for Alzheimer’s clinical trials involving people with intellectual disabilities